However, IDC with both TP53 mutation and MYC amplification showed a significantly higher histologic grading score when compared to those tumors with only a TP53 mutation or a MYC amplification (Fig. 4E,F, p < 0.05), suggesting a synergistic oncogenic effect by these two cancer driver genes. This evidence concerns the gene MYC and cancer.